An anatomy of thematic investing – ETF Stream

Thematic ETFs have been hugely popular over the past few years but what are the risks?

ETF.com categorises Cathie Woods Ark Innovation ETF (ARKK) as the largest thematic ETF in its database. Although ARKK is down approximately 60% over the last 12 months versus +1% for the Nasdaq 100, the ETF still manages almost $10bn assets.

However, ARKK does not really fit the definition of thematic investing which is a bet on certain structural trends rather than individual companies or sectors. A thematic portfolio should consist of one or several themes that are created from as many stocks as possible, ideally equal-weighted, in order to avoid firm-specific risks.

In contrast, ARKKs top 10 holdings constitute 60% of the ETFs portfolio which represents simply a concentrated actively managed portfolio comprised of growth stocks. Given the poor long-term track record of active managers, the odds of ARKK fully recovering and significantly outperforming the Nasdaq are fairly slim.

Although ARK Investment Management manages several ETFs that ensure some business longevity, it will be interesting to see if the firm will soon be forgotten or manages to revive its tarnished reputation. The quick rises and equally quick falls in fame are something where highly active and thematic investors overlap.

In this research note, we will analyse the birth, life and death of a theme.

Cannabis ETFs

We select cannabis stocks as a theme as that was one of the major ones over the last five years. Specifically, we choose ETFs that focus on cannabis stocks and are traded in the US. This is a universe of nine ETFs that cumulatively manage slightly above $2bn assets. One of the hallmarks of thematic investing is that the products are expensive.

The management fees of cannabis ETFs in the US range from 0.42% to 0.92%, compared to 0.09% for the SPDR S&P 500 ETF Trust, the worlds largest ETF (see Chart 1).

The fees can be even higher, for example, when considering short or leveraged ETPs like the Canadian-listed BetaPro Marijuana Companies Inverse ETF (2.0%) or BetaPro Marijuana Coms 2x Daily Bull ETF (2.06%).

The birth of a theme

Humans are suckers for stories and these explain much of human history. The Russian army has been told that Ukraine needs to be denazified and liberated which was an inspiring and motivating story for Russian soldiers until they met a fiercely resisting population that neither consisted of Nazis nor was seeking liberation.

Thematic investing is all about storytelling. Themes can be diverse, e.g. a country moving from a frontier to emerging market status, a resource becoming more scarce, a new technology about to revolutionise our lives and so on. The best themes are as easy to grasp for a retail as for an institutional investor. They are difficult to refute as they are about the future which can only be proven wrong in hindsight.

Back to cannabis stocks. The interest in legally profiting from cannabis has always been high but difficult to execute given the use of cannabis is a crime in most countries. Uruguay was the first country that legalised the recreational use of cannabis in 2013 but that did not matter much for investors. More relevant was when Canada followed in 2018. A number of cannabis companies completed IPOs in record time to raise capital for building their operations. ETFs providing exposure to this emerging space followed shortly.

An equal-weighted index of cannabis ETFs in the US outperformed the S&P 500 in parts of 2018 and 2019, mainly fuelled by the hope that the US would follow Uruguay and Canada.

The recreational use of cannabis had already been legalised in a few US states like Oregon, Washington and Colorado but it is still a federal crime that made it difficult for companies to operate in that space.

Legalising cannabis on federal level would be a game-changer and offer investors the opportunity to participate from potentially highly profitable and fast-growing businesses. A theme was born (see Chart 2).

The birth, life and death of a theme

The two characteristics of thematic investing are having a good story and attractive returns No matter how sexy a theme is, the majority of investors only hop onto the train once it started moving uphill. Naturally, this makes thematic investing so dangerous as it appeals to our love for stories and greed for making money. Stated differently, thematic investing is performance chasing with a narrative.

We can see the risk of buying into a theme when we view the performance of the cannabis stocks over a longer time period. These stocks performed in line with the S&P 500 between 2015 and 2017 and then outperformed strongly during the next two years when various hopes for a broader US legislation for the recreational use of cannabis emerged.

However, investors enthusiasm drove the companies valuations to levels that were not supported by fundamentals and the federal law in the US did not change. Eventually, mean-reversion settled in and the cannabis stocks significantly underperformed the S&P 500 since 2019. An investor that bought into the theme at its peak in 2019 would have lost more than 50%, compared to a gain of more than 100% in the US stock market.

The investor behaviour becomes clear when comparing the performance of a thematic product and its assets under management. We take the ETFMG Alternative Harvest ETF (MJ) as a case study. The ETF was launched in 2015 and has the longest track record of cannabis ETFs in the US (see Chart 3).

The assets under management were below $100m until the cannabis theme emerged in 2017 when assets jumped to over $1bn. However, as the performance deteriorated in 2019 and 2020, assets dropped accordingly.

Naturally, the assets of any investment product decrease as performance turns negative but it highlights that investors do not pursue a theme if the returns are unattractive. They are not true believers and are simply chasing performance (see Chart 4).

Further thoughts

The economy and world continuously evolve and change the way we live. Participating in and profiting from these changes as investors is a perfectly reasonable investment strategy. However, the implementation matters.

Pursuing this via thematic investing subjects our investment decision-making process to our biases that result in poor results. Better is to implement this systematically via trend following an asset class or momentum on stock level. It is far less exciting than chasing the latest story but creates a much better long-term narrative.

Nicolas Rabener is founder and CEO of FactorResearch

This article first appeared in ETF Insider, ETF Stream's monthly ETF magazine for professional investors in Europe. To access the full issue,click here.

Related articles

Have you seen our new ETF data tool?

Just click on any of the ETF links in the article above and you will get access to a whole host of data including:

Please note: The tool is provided by ETF Logic who shall process your personal data in accordance with their privacy policy.

See the article here:
An anatomy of thematic investing - ETF Stream

Anatomy of a Scandal Is the Quintessential British Show. Allow Me to Explain – Vogue

While the general public got shushed by Lorde, Netflix changed its payment plan. It also brought us Anatomy of a Scandal, a hugely successful Sienna Miller/Rupert Friend courtroom drama pivoting on the murky nuances of sexual consent. Though the core of the series deals with a very serious issue, Im still trying to work out why its been so captivating. Why is this particular cluster of one-hour episodes topping the Netflix charts?

Perhaps its Sienna Miller herself? Her hair is a melted halo. (Thats a good thing.) Her skin is flawless in a naturally dewyrather than powdery or filter-yway.And the initial scandal eerily echoes Siennas own post-bohemian It-girl rough patch. (Her former partner was revealed to be having an affair with their nanny.) Siennas lived through the myriad feels that come from public-domain humiliation, and we can feel that as she plays a woman trying to keep her shit together in front of the braying paparazzi.

Perhaps its simply the money that makes the show pop? Im the first to admit that my favorite genre is extremely rich people in extremely rich houses being somewhat dastardly. Rich women with a lot of feelings are crack to me, as they navigate being both liberated and held captive by their money. The things these women sacrifice! The biting of their tongues! The forest-y decals in their kitchens! Extreme wealth is always captivating, if only by way of having live-in staff and more Max Mara coats than you could wear in a lifetime.

Perhaps its all the power? Rupert Friend is compartmentally hotall the pieces are there for heatbut the temperature runs in the minuses. Theres simply nothing less sexy than a Tory MP, especially one whos so particular about which women he treats with respect, and which ones he disdains. His sense of his own familial legacy is frankly revolting; the idea that family cannot fail, even at the expense of truth, perversely prevails. Its hard to look away from his Machiavellian power plays. And needless to say, Friends achingly Tory haircutsomehow too square and too soft, chiseled from a sad putty of inexhaustible entitlementstamps out any last embers of desire.

Or perhaps its the shows overt Britishness I cant get enough of? The stately House of Commons canteen. The stiff upper lip-ness. Anatomy is both a frothy and forensic look at dishonor, silly in is rather out-there anti-reality TV effectsSienna falls through the courtroom like Alice down the rabbit hole; Friend is involved in a rather nasty hit-and-run with an invisible clown car. Theres certainly something slightly excruciating about the rape of a parliamentary intern juxtaposed with camera theatrics. But the show tackles the hard stuff, too; its an autopsy of the lives scandal touches as it ripples from the event. (It also takes us back to scandals of yore, and delivers the most farfetched plot twist in modern TV.)

More:
Anatomy of a Scandal Is the Quintessential British Show. Allow Me to Explain - Vogue

The Soothing Narration of Ellen Pompeo In ‘Grey’s Anatomy’ – The Blast

Its been on the air for nearly 20 seasons and currently sits as the longest-running hospital drama of all time, the Shonda Rhimes breakout hit, Greys Anatomyfollows the career of Dr. Meredith Grey all the way from intern to attending surgeon. Portrayed by Ellen Pompeo, Grey serves as the series protagonist and resident narrator, and while hers is the main voiceover for the series, Greys Anatomy doesnt shy away from the use of multiple narrators to tell the story.

Throughout its ongoing run, the drama centers on Meredith Greys perspective of the world and life between hospital walls. Her narration saturates the beginning and end of each episode, and provides an introspective look at the day-to-day challenges of her career, with real-life ordeals peppered into the narrative.

She begins each episode with a burning question, thought or assertion that sets a tone for whats to come over the next forty some-odd minutes of screentime. In every episode, theres a lesson to be learned or a notion to be challenged; the audience doesnt just follow Grey, but grows and learns with her. We overcome ordeals and trauma as she does. Meredith not only narrates the top, tail, and theme of each episode but presents it as if telling the story of how she came to be who she is at the time of telling it. By the end of each chapter, she tells us how she came away changed or wiser from the experience.

Most series title their premier as a pilot, but Greys Anatomy broke from the bland tradition in the most apropos way and named the first episode after the Beatles song, A Hard Days Night. As if to illustrate the interns first shift at Seattle Grace, the near-sleepless 48-hour stint serves as a jumping-off point for the series and introduces us to the core cast. Were given a glimpse into what its like to start out as an intern and all of the gritty details that come along with it.

Throughout the pilot, the audience is given allusions to how prominent our main characters mother is in the medical field and elusive hints to the legacy she left.

For most of the episode, the audience is left to wonder why Meredith shies away from the mere mention of her mother, and were left to assume that shes simply attempting to distance herself from the senior Greys illustrious shadow. But in a heart-wrenching twist, the narration comes full circle, and by the end of the episode, we come to learn that the story being told isnt directed at us, but at Merideths mother who has Alzheimers.

Its a heartbreaking blow to the audience that puts the events of the episode into an uncanny perspective, but it wasnt initially planned that way.

Merediths voice not only welcomes the audience into her world but shows them her innermost thoughts and feelings; its become a staple for the long-enduring series that carried forward throughout nearly two decades of airtime.

Its become nearly impossible to imagine the series without it.

While most series that use a narrator plan their method of story-telling around the voice-over, that wasnt the case with Greys Anatomy. After filming had finished for the pilot, and the first episode was on the cutting room floor, Shonda Rhimes noticed something was missing.

She felt that there was a human element needed.

In a well-placed effort to tie everything together, and bring the story a much-needed sense of clarity, Rhimes decided to add Ellen Pompeos voice-over after the fact. While her narration is usually limited to the beginning and end of each episode, it never fails to drive home the events of each chapter to Greys Anatomy viewers and keep us in line with Merediths point of view.

That being said, Meredith isnt the only narrator we hear in the enduring series.

As difficult as it is to imagine the series without the narration of Dr. Meredith Grey at the beginning and end of each episode, shes not our only narrator. In fact, we have at least nine.

Throughout Greys Anatomy, we grow to love (or hate) the supporting cast members. As they come into their own over the course of the series, some stay and some go, but their presence remains one of the deepest facets of the plot. Theyre not just supporting roles theyre friends, colleagues and rivals. They drive the story forward in their own unique ways and play off of each other to create a cohesive narrative that contrasts Merediths own. Most of the supporting cast members even narrate the odd episode here and there to add an inside look at who they are as individuals. Each of these characters is still the lead role in their own story, and through the use of their own distinct voiceovers, the audience gets to catch a glimpse of who they are on the inside and not only watch them grow but see how they perceive Meredith as well.

As viewers, we know why Greys Anatomy has such a turbulent storyline; its a drama. But say we were to inhabit the same world as Meredith Grey, what then? If the events of Greys Anatomy were told to you firsthand, would you believe the story outright, or take it with a grain of salt? In the real world, as hectic as any given hospital may be, nothing is that over-the-top, and it stands to reason that at least some of the narrative is embellished.

Or, a much darker and grounded truth is behind it.

Drama or not, Greys Anatomy is still a medical show, and the underlying plot device is equally based in medical reality. Knowing that Meredith was found to have the genetic markers for Alzheimers, just like her mother, its far more likely that the story comes full circle from the pilot episode, and a much older Merideth is telling the story to her children but is now herself suffering from Alzheimers.

Serving as Shonda Rhimes first breakout hit, Greys Anatomy has been on the air since 2005 and reached the official milestone of longest-running hospital drama to date currently closing in on its 19th season. Its been the springboard for multiple acting careers and become something of a cultural institution for multiple generations of fans who have grown up watching it. The series has been nominated for 39 awards over its nearly two-decade runtime, but only received five actual awards none of which went to the lead.

Even though Ellen Pompeo has been the star and focus of the series for nearly 20 years, and become one of the highest-paid female actors because of it, shes never won an award for her long-standing lead role.

Kim Handysides is an award-winning voice artist, coach and thought leader in her industry. Her narrations have been heard on Discovery, Netflix, and the major networks, in iMax, the White House and the Smithsonian.

Read more here:
The Soothing Narration of Ellen Pompeo In 'Grey's Anatomy' - The Blast

How a phone call from Boris inspired me to write Anatomy of a Scandal – The Spectator

News of the Anatomy of a Scandal billboards on Sunset Boulevard sits in my DMs while I shepherd my teens through the preschool chaos. Its the morning I drive my youngest to school. Have you seen my goggles? he calls, while I covertly flick to the Insta app on my phone and see that one of the executive producers of the Netflix show based on my thriller has sent me four messages. My heart trips. I may have written an international bestselling novel developed by the Big Little Lies dream team, but imposter syndrome rages; my default response that Im about to be found out. Only, there they are: photos of vast billboards depicting the series leads - Sienna Miller, Michelle Dockery, Rupert Friend, Naomi Scott, and Josette Simon looking suitably noirish against a hazy LA sky. Its the latest in a series of discombobulating moments, but I havent time to dwell on it. Come on, comes the cry from the hall. Were going to be late!

It's one degree and sleeting by the time I drop the boy and look at the image again, on a freezing dog walk. I fire off a tweet, and head along an East Anglian field, sleet driving into my face. Hands in my pockets, I can feel my phone vibrating with congratulatory messages from other authors. Take a selfie! suggests one. Jump on a plane! says another. I think of my to-do list: the articles to be written; the small matter of dog and children; covid just experienced, still clouding my brain. The scene is bleak: grey skies; ploughed-up brassicas; a biting wind whistling from Siberia, but I smile. I dont need to fly 5,400 miles to see the billboards in person. The six-part series based on my thriller about power, privilege and consent is being paraded along the road to Hollywoods studios. Its enough to know that its there.

It's been quite the journey. When I wrote it, back in 2016, I had no idea if anyone would want to publish it. A former news reporter and political correspondent on the Guardian, Id taken voluntary redundancy after my second baby, the childcare juggle/two-hour commute seeming insurmountable and financially impossible with a husband doing anti-social shifts. My first two novels didnt trouble the UK bestseller lists, but then came Anatomy, partly inspired by a phone call Id taken from Boris Johnson, back in late 2004, over his affair with Petronella Wyatt. Drawing on my time at Oxford, my experience at Westminster, and my court reporting, its been sold to 24 countries and was swiftly snapped up by Made Up Stories, 3dot Productions and David E Kelley. Four years later, its now one of the most watched shows on Netflix.

And its been a ride. Ill never forget going on set at the end of the third lockdown and meeting an Ugg-shodden Sienna, Michelle, and Josette (covid protocols meant the Shepperton studio in which they were filming the court scenes was freezing) or discussing consent and privilege with an emotionally intelligent Rupert Friend. Ive felt a quiet thrill hearing my lines voiced by these actors, while recognising that something fresh has been created: that my baby has developed way beyond my pages into something gripping to be screened in 190 countries; is no longer mine. Of course, there are changes its twistier and more sumptuous but Im thrilled it remains faithful to the tone of my thriller with its key themes of entitlement and consent. The cast have been doing sterling work, touring the US chat shows, and, in Siennas case, being frank about the parallels with her own life. Reading and listening to her speaking so passionately about its relevance is another pinch-me moment. It couldnt be more timely.

The Conservatives have helped with the marketing. That was my immediate, irreverent response to the recent allegations againstTory backbencher David Warburton. Whenever Ive worried that Anatomy might feel outdated, another politician does something abusive or entitled: Charlie Elphicke; Matt Hancock; the PM and Partygate; and now the MP for Somerton and Frome. It means rewriting a T2 front, originally slated for transmission day, but its a pleasure. A middle-aged man accused of sexually assaulting two younger women while his wife stands dutifully by him? Sounds rather familiar.

Weve grabbed a few days in north Cornwall, though the idea of my taking a holiday at the most exciting point of my career is clearly stupid. Nevertheless, its wonderful to be here. The historian A.L. Rowse described the county as the land of my content and I feel similarly about the spot Ive been visiting since I was a child, and from where my mums family hail. My literary claim to fame used to be that a distant relative, one Hilda Jelbert, was DH Lawrences 14-year-old maid at Zennor. After scouring Padstow Tesco, where Anatomy of a Scandal is on the front of two magazines, inside several others, and the Times, I realise thats about to change.

Visit link:
How a phone call from Boris inspired me to write Anatomy of a Scandal - The Spectator

Anatomy of Tyson Fury’s perfect punch that exposed Dillian Whyte’s Achilles heel – The Telegraph

Indeed, Steward had been hinting in fight week that Fury would deliver a special finish to the fight. Fury, whose boxing IQ marks the 6ft 9ins fighter out as markedly elite - created the finish seemingly from nowhere, but it was not the case: the uppercut - a punch which leaves the exponent more open to counters, yet highly effective - was not to be used by Fury until there was a clear opening. That dramatic denouement came in the sixth round, with Fury by then commanding against a tiring, frustrated Whyte, having won all of the five previous rounds on my card.

It was a scrappy fight in parts, with Whyte unable to close the gap easily on Fury. Whyte began the opening round cleverly, switching stance to southpaw, in an effort to nullify Fury finding a rhythm early with his typically effective jab. Yet still Fury claimed the first round as they danced in space in a phoney war as they felt each other out. The second round was scant in punches landed, but Fury landed effectively with a left hand, as Whyte, already frustrated, threw wild punches as they tied up on the ropes - to little effect.

For three more rounds, Fury controlled the pace, always wary of Whyte's dangerous counter left hook, moving smartly off after no more than two punches, and more often using single shots. In the fourth, Fury remonstrated with Whyte after the heads clashed, with referee Lyson warning Whyte. Whytes right eye that was cut and beginning to swell, but as the two came together, the south Londoner landed his famed left hook for the first time. Lyson warned Fury about using his head. It was a disjointed, bad-tempered round.

Fury did not open up with combinations until the fifth, throwing a series of jabs, as he felt Whyte's physical resilience wane. But then the pattern was set - as Fury controlled the distance from the outside with Whyte battling, unsuccessfully, to close the space between them to get his shots off.

That fifth stanza was a particularly strong round for Fury, boxing in a tight circle, as the champion pressed home against a rival he was mastering. Indeed, Fury picked Whyte apart with the jab, right hands, and body shots, staying ahead at all times in the contest.

It was in round six, however, that Fury displayed why he must be seen as the world No 1 towering over his rivals. He used his height and reach advantages, and moved fluidly and effectively, beating his foe to the punch before delivering the blow that Whyte did not see coming, to bring the curtain down on the night, if not his career. Time will tell on the latter.

See original here:
Anatomy of Tyson Fury's perfect punch that exposed Dillian Whyte's Achilles heel - The Telegraph

From The First Lady, Gaslit to Anatomy of a Scandal, women in US politics are stepping out of their shadows – Firstpost

These stories, from Julia Roberts-starrer Gaslit on Lionsgate Play to The First Lady on Voot Select, have ensured that the political wife will not be viewed as a doormat.

When Bill Clinton first became the US president, American media was flush with reports of interference and controlling approaches by his wife, Hillary.

She was called a meddler, power hungry, and over ambitious, and criticised for her personal choices, including her haircut (a bob) regularly. From being the worlds greatest defender of democracy (self-styled and selective as we see in the Ukraine situation) to being a cosmopolitan land for all cultures and people, America has a visible and loud conservative strand that puts political wives in their place.

But on OTT stories of political wives, their presence and their lives have brought engaging shows. These women have little agency in actual policy making, decisions or influence over politicians and their choices. But they have -been role models for wives and women in a white-dominated national narrative; and in the case of the Obamas, a mark of strength and independence that included women across all cultures. What they have faced and tackled is symbolic to what other women have also had to deal with, irrespective of incomes and social status.

The First Lady (on Voot Select) is one such show. It holds three parallel narratives of first ladies across generations, Michelle Obama, Betty Ford, and Eleanor Roosevelt, freely flowing between their struggles and successes in the role of Americas first wife. Directed by Susanne Bier, the core of this show is the sublime subjugation of self and identity that smart, self-made women have to accept when they become wife to the American President.

Still from The First Lady

The show stars Viola Davis, Michelle Pfeiffer, and Gillian Anderson as first ladies. But while its acting and narrative has received mixed responses, the series has successfully shown the sacrifice that being married to the worlds most powerful man will bring. Each woman Michelle, Betty, and Eleanor was instrumental to making their husbands steadily, to become President. As the presidency sets in and a move to the White House becomes imperative, they become second to the institution at all levels.

After that, keeping their husbands safe, ensuring they remain functional, and balancing the never-ending media glare of public life with motherhood take over their lives during the presidential terms. Their priorities donot matter. Living this life has challenges and unexpected difficulties. The First Lady has to handle all of this with grace.

The series touches upon this reality, where women often have to give up their identities and professional or personal goals for the sake of husbands and families;a fact of life for many in todays world. That makes their stories connect with multiple women at a personal level.

The political wife who does not try to rebel against convention, one who holds conservative views and finds the spotlight, is the crux of Mrs America (Hotstar). Cate Blanchett delivers a fabulous performance as Phyllis Schlafly, a woman activist who worked a nationwide Stop Era campaign against equal rights movement in America. The housewife who mothered six kids and typed endless letters, and became a TV celebrity with her superficial politically minded appearances, became a nobody once the Ronald Reagan administration came to power.

Cate Blanchett in Mrs America

These are lesser known stories of women who worked in political activism from the fringes, carving a space for themselves without always being welcome. One such woman, Martha Mitchell, is the central character of Gaslit,a series on the fall out of Watergate in the Richard Nixon administration (on Lionsgate Play). The show has received very positive reviews, especially Julia Roberts as Martha Mitchell, with equally strong performances by Betty Gilpin and Sean Penn, barely recognisable under prosthetics as Nixon Attorney General John Mitchell.

Martha Mitchell had gotten herself in serious trouble with the dangerous Nixon inside men when she spoke out against the president and his team, calling them out on the Watergate scandal. She was forced to live in a hotel room to silence her, for she was popular with the media for her unfiltered, honest interviews. In a presidency shrouded with opacity, Martha was fresh and absolutely open in her criticism. John Mitchell, on the other hand, was dodgy in his statements and ways of operation. Through their lives and gradually splintering marriage, Gaslit captures a corrupt political era with potentially dangerous consequences well. Marthas story resonates till date, for political wives still have to hold their peace and shut up for the 'greater good.'

The latest limited series, Anatomy of a Scandal, has a similar theme from fiction. From SJ Clarkson and David E Kelly (co-creators of Big Little Lies), this is about a British MPs wife who has to stand strong even as her husband faces rape and sexual harassment charges. The series puts her state of mind at the center of its plot, offering insight on the difficulty of living through public scandals without being involved in them.

Still from Anatomy of a Scandal

Women are making up for the bulk of engaging stories on OTT and film in recent years. The political wife, beyond the conniving, over-ambitious one like in House of Cards, is a human being. Her emotions, intent, and experiences constitute engaging stories with universal appeal. She is not just a doormat. These stories have ensured that she will not be viewed as one.

Archita Kashyap is an experienced journalist and writer on film, music, and pop culture. She has handled entertainment content for broadcast news and digital platforms over 15 years.

Read all theLatest News,Trending News,Cricket News,Bollywood News,India NewsandEntertainment Newshere. Follow us onFacebook,TwitterandInstagram.

See the original post here:
From The First Lady, Gaslit to Anatomy of a Scandal, women in US politics are stepping out of their shadows - Firstpost

A wealthy woman who doesnt need logos: The anatomy of soft power dressing – Sydney Morning Herald

Soft-power dressing has arrived in the unlikely form of reformed boho disciple Sienna Miller who stars in the Netflix series Anatomy of a Scandal.

Playing Sophie, the wife of a wealthy British politician accused of rape, Millers wardrobe expresses an elegance unsullied by logos, with a cream crpe dress from The Row, cape from Stella McCartney and vintage Celine pieces by minimalist designer Phoebe Philo.

Sienna Miller as Sophie in the Netflix series Anatomy of a Scandal defines soft power dressing with rich fabrics, neutral tones and the strategic use of white.Credit:Netflix

If the spacious home, cut-glass accent and in-laws with a country pile fail to communicate Sophies privilege, the sight of her cooking dinner in a white knit cardigan, without an apron, drives the message home.

The closest a spouse of a British politician has come to such polish is Samantha Cameron, wife of former Prime Minister of the United Kingdom David Cameron. As a nod to those in the know, during one of her accused husbands high drama court appearances Sophie wears a printed Lottie midi-dress from Samantha Camerons label Cefinn, beneath her signature Manuela coat from Max Mara.

This is the female equivalent of Succession dressing, where billionaires wear Loro Piana cashmere baseball caps, Maison Margiela T-shirts and Barbour jackets, overshadowing the women. Australian actress Sarah Snook as heiress Shiv started Succession strongly in turtlenecks and backless Gabriella Hearts knit dresses, but her wardrobe took a nosedive last season into ill-fitting office wear, letting the men take centre stage. Sophies soft power dressing in neutral knits and body-skimming dresses is a worthy successor to wealthy women dressing.

While the subtle and expensive look cultivated by Miller and Anatomy of a Scandals costume designer Sam Perry for Sophie is bewitching viewers, it might not translate easily to some Australian cities.

The Manuela coat from Max Mara, $4870; Larina dress, The Row, $1662; Lottie dress, Ceffin $699

Im all about stealth wealth, says Joshua Penn, co-owner of Belinda fashion boutiques. I think its a very Upper East Side, New Yorker way of dressing powerfully. Its that wealthy woman who doesnt need logos to show that shes made it. Its toned down. Its tailored. Its beautiful.

Occasionally theres a few women who dress like that, Penn says of his Australian clientele. I feel that Sydney is more of a Los Angeles vibe where everything is a bit more glittery, booby and just more. That understatement is more of a Melbourne customer who will pick a handbag from The Row instead of a Birkin or Chanel bag. We sell The Row handbags in Melbourne and not in Sydney. People in Sydney want the one that says Im wealthy.

Read more:
A wealthy woman who doesnt need logos: The anatomy of soft power dressing - Sydney Morning Herald

Global Resveratrol Market 2022 Research Analysis DSM, Evolva, Sabinsa, InterHealth Ripon College Days – Ripon College Days

The recent report named Global Resveratrol Market from 2022 to 2028 has been released by MarketsandResearch.biz. The objective of the report is to cater the demand from varied verticals involved in the Resveratrol market. The report presents the examined and processed data from primary and secondary sources. The raw data is passed through different stages such as deduction, formulation and validation.

The report is specifically prepared for the clients aiming to expand their business or enter into the Resveratrol market. There are key components such as regional analysis, company profiling and segmentation analysis which will help the companies to move further with their strategies. Also, the new entrants can analyze the level of competition in the market and can also understand the barriers to entry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/259022

Sections of the report

The Resveratrol market is fragmented into regions, in order to provide the exact market share and growth rate of the individual regions. The report discusses about the following countries:

The brief information about operating segments has been provided in the Resveratrol market. Two major segments included in the report are:

Apart from these, company profiling section has also been included in the final report. The market players involved in the manufacturing and distribution processes are:

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/259022/global-resveratrol-market-2022-by-manufacturers-regions-type-and-application-forecast-to-2028

The product/service that a firm has developed with the help of its R&D knowledge and technology, as well as their unique selling proposition, are the major differentiating factors.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on 1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: 1-201-465-4211Email: sales@marketsandresearch.biz

Read more from the original source:
Global Resveratrol Market 2022 Research Analysis DSM, Evolva, Sabinsa, InterHealth Ripon College Days - Ripon College Days

Bad Fat? Red Wine Could Fight That, Researchers Believe – Wine Spectator

When it comes to alcohol and health, does it matter what you drink? A new study has found a link between moderate red wine consumption and decreased levels of visceral fat, the tricky-to-lose "bad fat" that builds up with age and increases risk of heart disease and stroke. The study also found that while white wine consumption had no impact on bad fat, it did increase bone mineral density, a key marker of health in older adults. People who drank beer or spirits had increased levels of visceral fat.

The study, published in February in the journal Obesity Science and Practice, was led by Brittany Larsen, a Ph.D. candidate in neuroscience at Iowa State University, and overseen by Dr. Auriel Willette. The team analyzed lifestyle and body composition data from 1,869 participants in the U.K. Biobank Study, a biomedical database built by collecting detailed health information from over 500,000 U.K. residents.

While many studies about the health effects of drinking focus on the quantity of alcohol consumed, but not the type, this study analyzed the distinct impacts of four different beverage classes: beer and cider, white and sparkling wine, red wine and spirits. "To best assess how alcohol may influence body composition, one must consider the patterns of usage for different types of alcohol rather than simply gauging alcohol consumption as a whole," the authors wrote.

There are two competing hypotheses about how alcohol affects body composition, they continue. In some studies, alcohol has been shown "to promote fat retention by reducing lipid oxidation." In other words, not only is alcohol a source of extra calories (the so-called "empty calorie" hypothesis), but it actually slows the rate at which the body burns fat. Another hypothesis is that alcohol can "hinder caloric absorption and increase energy expenditure when consumed concomitantly with meals, which may, in turn, encourage weight loss."

The Iowa State scientists argue that focusing on the type of alcohol consumed could clarify alcohol's apparently contradictory risks and benefits. Their research indicates that while spirits and beer may well be empty calories, wine is anything but, and even "appears to help curb appetite," Larsen told Wine Spectator. As the study succinctly puts it, "greater beer and spirit consumptions have been correlated with higher waist-to-hip ratio. Conversely, wine has largely shown null or inverse associations with waist-to-hip ratio."

Larsen and Willette say wine's polyphenols are likely responsible for its health benefits. Resveratrol, a well-known polyphenol found in red wine, "may reduce inflammation and discourage fat storage." They attribute white wine's bone-building effect to protocatechuic acid, a lesser-known polyphenol which "aids in the reduction of bone loss." White wine contains nearly twice as much protocatechuic acid as red wine, which could explain why red wine did not show similar bone-strengthening activity.

Likewise, red wine contains much more resveratrol than white wine, which may be why white wine had no effect on visceral fat. Polyphenols hold rich possibilities for future study, Larsen said. "It is absolutely possible that there are polyphenols that have yet to be discovered that could have instead been responsible for explaining this association between white wine consumption and greater bone mineral density."

The authors are transparent about the study's limitations. The subjects were all white residents of the U.K. between 40 and 80 years old. It's unclear how the study's findings apply to other demographicsthough Larsen believes that "the results would [likely] be similarly applicable to older individuals of other races." Alcohol consumption and lifestyle data were self-reported, and while the study controlled for factors such as sex, diet, exercise and tobacco use, other factors besides alcohol consumption could have contributed to the observed health outcomes.

What should wine drinkers and healthcare professionals take away from the study? When it comes to health, "not all alcohol is created equally," said Larsen. It's good to be specific when talking to patients and evaluating one's own drinking habits. "Older adults frequently hear that drinking alcohol is beneficial for their hearts," Larsen said, but "wine may actually be the [only] alcoholic beverage to potentially offer benefits."

Instead of basing guidelines on a standard number of drinks per week, it could help to break down alcohol consumption by type. In particular, moderate consumption of both red and white wine, with limited intake of beer and spirits, may offer maximum potential health upsides while minimizing risks.

"Consuming a mix of both types of wines in moderation [is] more likely to offer a greater range of benefits than drinking one type of wine consistently, as each type of wine does appear to offer unique health benefits to body composition in older adults," said Larsen. The authors caution, however, that current non-drinkers should not start drinking alcohol solely for the potential health benefits.

Want to learn more about how wine can be part of a healthy lifestyle? Sign up for Wine Spectator's free Wine & Healthy Living e-mail newsletter and get the latest health news, feel-good recipes, wellness tips and more delivered straight to your inbox every other week!

See the article here:
Bad Fat? Red Wine Could Fight That, Researchers Believe - Wine Spectator

The Importance of Nutraceuticals in COVID-19: What’s the Role of Resveratrol? – DocWire News

This article was originally published here

Molecules. 2022 Apr 7;27(8):2376. doi: 10.3390/molecules27082376.

ABSTRACT

Since COVID-19 has affected global public health, there has been an urgency to find a solution to limit both the number of infections, and the aggressiveness of the disease once infected. The main characteristic of this infection is represented by a strong alteration of the immune system which, day by day, increases the risk of mortality, and can lead to a multiorgan dysfunction. Because nutritional profile can influence patients immunity, we focus our interest on resveratrol, a polyphenolic compound known for its immunomodulating and anti-inflammatory properties. We reviewed all the information concerning the different roles of resveratrol in COVID-19 pathophysiology using PubMed and Scopus as the main databases. Interestingly, we find out that resveratrol may exert its role through different mechanisms. In fact, it has antiviral activity inhibiting virus entrance in cells and viral replication. Resveratrol also improves autophagy and decreases pro-inflammatory agents expression acting as an anti-inflammatory agent. It regulates immune cell response and pro-inflammatory cytokines and prevents the onset of thrombotic events that usually occur in COVID-19 patients. Since resveratrol acts through different mechanisms, the effect could be enhanced, making a totally natural agent particularly effective as an adjuvant in anti COVID-19 therapy.

PMID:35458574 | DOI:10.3390/molecules27082376

See the rest here:
The Importance of Nutraceuticals in COVID-19: What's the Role of Resveratrol? - DocWire News

Easy ways to get creative with grapes – Times of Oman

Grapes not only taste great, they are good for you, too! Grapes are a natural source of polyphenols, which help protect cell health and promote cell function. Grapes also are a good source of Vitamin K, which is vital for blood clotting and healthy bones. Finally, the resveratrol in grapes positively influences immune function. That's a whole bunch of healthy for 90 calories per 3/4 cup serving.

Boost your breakfast. Try grapes with granola, yogurt and honey to get your morning off to a sweet start.Make salads more satisfying. Cut grapes in half, and add to your favorite green or grain salads for some added crunch and juicy goodness.Sweeten up snack time. Mix fresh grapes with nuts and dark chocolate, or freeze them to get mini popsicles. Make savoury more special. Grapes add a unique twist when paired with goat cheese on a pizza, or as a crostini appetizer topping alongside prosciutto and basil. Dazzle your desserts. You can make a gorgeous grape tart with just a few ingredients: a store-bought crust, a mixture of mascarpone cheese, powdered sugar and whipping cream and fresh grapes for the topping. So simple, but it will look like you spent all day in the kitchen.

Originally posted here:
Easy ways to get creative with grapes - Times of Oman

The Benefits of Berries Include Fiber and Fighting Inflammation – runnersworld.com

Theres a solid reason why everything from sour candies and cereals to antacids and energy gels come berry-flavored. Its a crowd-pleasing, sweet flavor. But besides the undeniable deliciousness of artificially-flavored berry foods, the real deal is one of the best foods for runners. Blackberries, blueberries, cranberries, raspberries, and strawberriesas well as their less-common but still-stellar siblings, acai and gooseberriesare all jam-packed with nutrition and are remarkably versatile.

Any and all of the types of berries are a boon for your body and brain, and support for your fitness goalsoffering plenty of reasons why runners should get more of them in their diets. Here, all the benefits of berries and how they promote your overall health and performance.

According to 2021 data from the American Society for Nutrition, a mere 7 percent of Americans eat enough of one very important carbohydrate: fiber. While whole grains and vegetables are strong sources of fiber, fruitsomething that 80 percent of American adults dont eat enough ofis also a major vehicle for this important nutrient. Not only does fiber keep us full, but it also aids in digestion, supports heart health, and lowers risk for several chronic diseases, according to research.

Berries are among the best sources of dietary fiber in the fruit category, explains Michelle Hyman, RD, a registered dietitian at Simple Solutions Weight Loss in New York City. They also contain antioxidants and phytonutrients. Some varieties, such as strawberries, are even surprisingly great sources of vitamin C.

The nutritional value of berries differs slightly based on the type, but each one packs mega health benefits. Here, the nutrition facts per 1-cup serving of some of the most common raw berries, according to the USDA.

Strawberry nutrition facts:

Blueberry nutrition facts:

Blackberry nutrition facts:

Raspberry nutrition facts:

Cranberry nutrition facts:

Getting your five-a-day of fruit and veggies from any source has been linked to lower risk of mortality, per a meta-analysis published in March 2021 in the journal Circulation. But berries specifically offer a slew of health benefits:

Fruit as a whole category is known to fight inflammation, Hyman says, which may be of benefit for individuals that participate in high-intensity training like running.

Vitamin C, quercetin (a flavonoid), and manganese function as antioxidants in the body, adds Mary Stewart, RD, a registered dietitian and the founder of Cultivate Nutrition in Dallas. This and the anthocyanins (polyphenols) that lend the vibrant color to berries makes them especially powerful at combating chronic inflammation caused by stress, unhealthy food choices, and lack of or too much physical activity.

In addition to being anti-inflammatory, berries offer antioxidant properties that can help combat fatigue and promote recovery, explains Frances Largeman-Roth, RDN, a Dobbs Ferry, New York-based nutrition expert and avid runner.

Research suggests that blueberry powder supplementation can stave off the blood lactate response in running, potentially allowing you to go longer or at a higher intensity without fatigue, Largeman-Roth says. (Full disclosure: The U.S. Highbush Blueberry Council funded the study.)

Berries, one of the best carbs for runners, are also among the most filling ingredients to add to your post-workout snack or smoothiethats thanks to their fiber content. Raspberries and blackberries are particularly potent in fiber, a key nutrient for weight management, gut health and reducing risk of chronic disease, Stewart says.

Berries of all kinds feed your gut with soluble fiber, which not only helps keep you fuller longer than, say, potato chips, because its slower to digest, but also blocks the absorption of some of the fat and cholesterol in your bloodstream.

Research proves that eating berries three times per week or more may lead to lower risk for type 2 diabetes and heart attacks. Adults who fall into the overweight and obese categories who eat 1 cup of blueberries each day for six months report notable improvements in heart health, reports a study published in the American Journal of Clinical Nutrition in June 2019.

All berries come packed with vitamin C, no supplementation required, and strawberries are an especially good source. (A cup of strawberries actually has more vitamin C than an orange, according to the National Institutes of Health.)

Vitamin C is an antioxidant that helps support a healthy immune system and protect cells from free radical damage, Largeman-Roth says.

Speaking of free radicals, the antioxidants in berries, such as anthocyanins, ellagic acid, and resveratrol, has been correlated with lower risk for several cancers, including breast cancer, cancers of the GI tract, and oral cancers. This may be in part due to the antioxidants ability to detoxify carcinogens that may harm DNA during the cancer development process.

Crank up the color and the nutrition of any meal of the day with these unexpected ideas from Hyman, Stewart, and Largeman-Roth:

Just keep in mind: As with any food or beverage, portion size is key. Berries are a high-fiber food and although this is a great attribute when evaluating the nutrient density of a food, consuming too much fiber too fast can lead to digestive discomfort, like bloating or constipation, Stewart says. If youre new to consuming berries, start with a small serving of to 1 cup and drink plenty of water. Also, begin by incorporating berries into your diet after workouts, rather than before until you know how your digestive system responds.

Athletes, including runners, may experience exercise-induced oxidative stress and, therefore, consuming adequate amounts of anti-inflammatory foods like berries, will support in recovery, Stewart says.

If it fits your budget and you can find them, stock up on organic berries, Stewart suggests. Thats because strawberries, blueberries, and raspberries are consistently ranked among the highest fruits in terms of pesticide residue, per the Environmental Working Group. This can be significantly improved by buying organic produce, Stewart adds.

Whether you buy them fresh or frozen, organic or non-organic, the goal is getting in your two to four servings of fruit per day, with berries being a top choice.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

See the original post here:
The Benefits of Berries Include Fiber and Fighting Inflammation - runnersworld.com

More brands hopping on the bidirectional beauty bandwagon – NutraIngredients-usa.com

Topicals with supplementstraditionally two fragmented industriesare increasingly being sold in combination. NutraScience Labs is one company thats embracing the bidirectional beauty trend something Gene Bruno calls the holy grail of skincare.

The combinations of beauty from the inside out and the outside in is the future and well, now it's the present, but that's the way that so many different brands I see are going. They recognize that that's how you get the best possible result. Instead of having to wait six to eight weeks to see something, you see something immediately. And conversely, if you're just using a topical you use it and then you dont see the long-term effects. Now you see both short-term and long-term and that is the wave of the future,Bruno said at Expo West.

Another trend that Bruno is seeing is the proliferation of gummies, as a generation raised on Flintstones vitamins is no longer 10 million strong and growingbut all grown up.

For years I was not a big proponent of gummies, but the technology in gummies has improvedto the extent that now you can make a gummy and have good stability. Now, the trick is only to make it taste palatable and we're pretty pleased because we've just introduced for the first time some gummy products, including collagen gummies for skin, keratin gummies for hair, and a resveratrol gummy which has many applications. It's a new foray for us into the gummy world, but we're really pleased because like all of our products clinically relevant doses of the right stuff and the right forms to give a good result. So we're really excited about this whole new direction and we still have all the encapsulated products and everything else we have, but it's just something new and already were getting some pretty good feedback, said Bruno.

When looking at consumer surveys, Bruno said capsules remain on top but gummies are trending upwards at an almost-meteoric rate compared to other, more traditional delivery methods.

We see that trajectory of gummies and alternative delivery forms increasing at such a rate. People love that alternative delivery form, especially like gen Z or Millennials. My generation, the Baby Boomers, not as much, but so many people are getting into that and so you have to keep up with the times.

View post:
More brands hopping on the bidirectional beauty bandwagon - NutraIngredients-usa.com

Polyphenol Market Provides an In-Depth Insight of Sales, Revenue, Analysis of Growth Factors and Upcoming Trends, Opportunities by Types and…

Polyphenols are a structural class of mainly natural, but also synthetic or semisynthetic, organic chemicals characterized by the presence of large multiples of phenol structural units. . Global Polyphenol Market 2022 Worldwide Market Reports offers dynamic data of the Polyphenol Market. The report gives a start to finish examination of market size, share, future patterns, development openings and gauge to 2027. Likewise gives the inside and out examination the around the world, territorial and nation level. The Polyphenol Market is expected to mirror a positive development pattern in approaching years and this factor which is significant and steady to the business. Its huge vault gives an insightful outline of market that will serve to new and existing players to take significant choices.

Please click the link below to get a sample report :https://www.worldwidemarketreports.com/sample/711143

Top Key Vendors of this Market are:

Chr. Hansen Cargill Barry Callebaut Seppic

For this report, an advanced research team has performed exhaustive analysis and detailed analysis of all types of information available in the Polyphenol market, followed by access to an approved data infrastructure and long term market database. According to a new report, the global Polyphenol market is projected to reach 1 million units by 2027, growing over the next 5 years. This report studies the market size, supply and demand, competition, key industry operations and SWOT analysis of Polyphenol which will assist organizations in identifying the strengths, weaknesses, opportunities and threats related to business competition. It also provides scientific forecasts for the future development of the Polyphenol industry. This report can help investors understand the current market situation of Polyphenol company, forecast the future of Polyphenol company, identify investment opportunities and recommend investment plans, production plans and marketing plans.

Polyphenol Market breakdown by Type:

Polyphenol Resveratrol Phenolic Acids Catechin

Polyphenol Market breakdown by application:

Functional Food Functional Beverages Dietary Supplements

Polyphenol Market Analysis of COVID-19 Impact:

We have been tracking the direct impact of COVID-19 on this market and the indirect impact of other industries. The final report adds an analysis of the impact of COVID-19 on this industry. In the report on the global Polyphenol market, experts have mentioned the post-war impact of COVID-19. The report details the advantages and disadvantages in terms of the financial and market growth achieved during this crisis. Despite the severe economic crisis, the Polyphenol market has embraced new development strategies and technologies to recover. Markets are starting to look for different funding and business approaches to maintain themselves on both regional and global platforms.

To Understand how covid-19 impact is covered in this reports :https://www.worldwidemarketreports.com/covidimpact/711143

Regions Covered in the Polyphenol Market Report 2022: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Companies operating in the Polyphenol market aim to expand their production capacity, especially by establishing new production units in emerging markets. We also focus on strategic acquisitions and acquisitions to strengthen our geographic presence in the market. Key market players are also focusing on developing technologies to increase production capacity with minimal operating costs. The latest study of the Polyphenol market covers all the strategies and success factors of the key market makers.

Click here to Enquiry before buy this report :https://www.worldwidemarketreports.com/quiry/711143

This Report Also Includes :

Worldwide market reports methodologyTactics and suggestions for new entrants.Segmentation analysisEconomic indicesCompanies strategic developmentsMarket growth drivers and restraintsSelected illustrations of the market penetrations and trends

Table of Contents :

Research scopeGlobal Polyphenol industryMarket dynamicsGlobal market segmentationNorth america market segmentEurope market segmentationAsia-pacific market segmentationSouth america market segmentationMiddle east and africa market segmentationCompetition of major playersMarket forecastReport summary statement

Key Questions Answered in the publishers Report on Polyphenol Market

1. What does this report covers ?2. Does this report estimates the current market size ?3. What are the key Segments offered in this report?4. Which market dynamics covered in this report?5. Does this report offer customization ?6. How will COVID-19 impact the Polyphenol market?7. Which companies are leading the Polyphenol market?8. How will changing trends impact the Polyphenol market?

Click here to get full report :https://www.worldwidemarketreports.com/buy/711143

The Polyphenol report provides extensive qualitative insights on the potential and niche segments or regions exhibiting favorable growth.

The report provides an extensive analysis of the current and emerging market trends and opportunities in the global Polyphenol market.

A comprehensive analysis of the factors that drive and restrict the growth of the Polyphenol market is provided.

An extensive analysis of the Polyphenol market is conducted by following key product positioning and monitoring the top competitors within the market framework.

The report provides detailed qualitative and quantitative analysis of current trends and future estimations that help evaluate the prevailing market opportunities.

The report also focuses on global important propulsion industry players of Global Polyphenol market providing data such as organization profiles, item pictures and specific, value, limit, cost, generation, income and contact data. Further investigations of upstream crude oil and gear and downstream interests have been completed. With tables and figures analyzing the entire global Polyphenol market, this exploration provides key insights on the state of the business and is a valuable source of direction and direction for organizations and people interested in the market. The global Polyphenol market development patterns and marketing channels are collapsing. Finally, the feasibility of a new speculative project is investigated and the review is usually closed.

Contact Us:Worldwide Market Reports,Tel: U.S. +1-415-871-0703U.K. +44-203-289-4040Japan +81-50-5539-1737Email: sales@worldwidemarketreports.comWebsite:https://www.worldwidemarketreports.com/

Other Reports:

Capsule Feeders Market 2022 Outlook Report, Growing Trends in Forecasted Period 2027 | Bosch Packaging Technology, Schaefer Technologies Inc, Torpac Inc., ACG Worldwide

Construction Vessels Market To Witness Huge Growth By 2027 with Top Key Players| Edison Chouest, Swire, Gulf Mark, Tidewater

ATM Outsourcing Market 2022 Detailed In New Research Report with Forecast to 2027 and Top Key Players: Cardtronics, ATMJ, Asseco, Fis

See the rest here:
Polyphenol Market Provides an In-Depth Insight of Sales, Revenue, Analysis of Growth Factors and Upcoming Trends, Opportunities by Types and...

Heres A List Of Essential Supplements That Women Need After Age 40 | Femina.in – Femina

Image:Shutterstock

Human nutritional requirements are rapidly evolving. Our diets lack the nutrient values that our bodies require, despite the fact that everyone is now aware of and embraces healthy eating. Furthermore, as people age, they tend to eat less, making it more difficult to ensure that their diet is varied enough to include all of the nutrients they require. Experts believe that women's bodies change dramatically throughout their lives and require optimal nutrition.

Hormone-related alterations, for example, promote weakening of the bones in postmenopausal women. To boost appetite and maintain muscle mass, doctors recommend getting as much exercise as possible and eating nutrient-dense foods instead of energy-dense foods, such as lean meats, eggs, low-fat dairy foods, fish, liver, nuts and seeds, legumes, fruit and vegetables, whole grain loaves of bread and cereals, explains Sahil Mehta, Managing Director and Founder of MuscleXP who feels a healthy lifestyle requires a combination of well-balanced nutrition and frequent exercise.

Health supplements with natural ingredients can help one to stay fit and strong in the face of adversity. The purpose of a food supplement is to provide a little something extra to your usual diet. They ensure that the individual receives a measured amount of essential nutrients and compensate for the low nutritional content of the different foods consumed. They assist people in getting the most nutrition from their healthy diet in order to reach their health goals. There is strong scientific data demonstrating that dietary supplements are beneficial for maintaining health and managing particular health disorders, adds Mehta, citing the example of women planning a pregnancy requiring folic acid to lower the chance of specific congenital defects.

The following are some of the expert-recommended supplements and nutrients for women over the age of 40.Omega-3: Helps maintain joint health, reduces hot flashes, lowers bad cholesterol, and protects against certain conditions such as osteoporosis and rheumatoid arthritis.Vitamin D: Pivotal to the absorption of calcium and maximising bone health, can reduce cognitive decline, lower the risk of all cancers, and act as an immunosuppressant in rheumatoid arthritis.Magnesium: Reduce the risk of oestrogen excess conditions (such as fibroids), lowers postmenopausal osteoporosis, and improves mood disorders.Vit B12: Prevent megaloblastic anemia, aid in cognitive function (memory issues, focus, and brain fog) during perimenopause or menopause, and lower the risk of age-related macular degeneration.Resveratrol: Associated with slowing down aspects of the ageing process, lowering inflammation and helping with symptoms related to perimenopause/ menopause.

Also Read: Substitute These Indian Superfoods For The Imported Ones

Read the rest here:
Heres A List Of Essential Supplements That Women Need After Age 40 | Femina.in - Femina

Apertura Gene Therapy Launches with $67M Series A Financing from Deerfield and an Innovative Technology Platform to Develop Genetic Medicines -…

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apertura Gene Therapy, a biotechnology company opening opportunities for treating debilitating diseases with limited options for patients, today announced that it has launched with a Series A financing of up to $67M from Deerfield Management Company to develop genetic medicines using platform technologies that address key limitations of genetic medicine delivery and expression. Deerfield Management has also committed additional operational support to further strengthen the companys ability to advance gene therapy discoveries.

Apertura is founded on a pair of platform technologies developed in the labs of Ben Deverman, Ph.D., Senior Director of Vector Engineering and Institute Scientist at the Broad Institute of MIT and Harvard, and Michael Greenberg, Ph.D., the Nathan Marsh Pusey Professor of Neurobiology and Chair of the Department of Neurobiology at Harvard Medical School (HMS). The companys platform leverages machine learning and high-throughput assays to engineer novel capsids, gene regulatory elements, such as promoters and enhancers, and payloads to simultaneously enhance multiple functions of gene therapies for greater translational potential.

With these platform technologies from the Broad Institute and Harvard University, Deerfield saw an opportunity to bring together and support a unique and comprehensive platform that could address technical challenges that have prevented gene therapy from reaching its full potential, said Dave Greenwald, Ph.D., Acting Chief Executive Officer of Apertura and Vice President, Business Development at Deerfield Management Company. While next-generation approaches to gene therapy have largely focused on the innovation of delivery vectors, Apertura has the potential to innovate simultaneously across delivery, expression, and payloads.

Ben Deverman, Scientific Founder of Apertura, said: When developing a gene therapy, it has been common to use naturally occurring serotype AAV capsids. The technology we have developed uses proprietary assays and machine learning to design custom AAV capsids that have the chosen characteristics for treating specific diseases, and we believe this approach will result in new and effective gene therapies.

Apertura has certain exclusive rights to AAV capsids developed in the Deverman Lab at the Broad Institute.

A separate sponsored research and licensing agreement with Harvard University, spearheaded by the Harvard Office of Technology Development, grants Apertura exclusive access to certain powerful methods of identifying cell type-specific genetic regulatory elements (GREs), including access to the Paralleled Enhancer Single-Cell Assay (PESCA) platform, developed in the Greenberg Lab at Harvard University.

A major challenge in developing effective gene therapies is having the payload of the therapy expressed at the correct level in target cells, said Greenberg. "The technology we have developed at Harvard Medical School overcomes this hurdle by targeting transgene expression to specific cell types, fine-tuning expression levels in these cells, and, at the same time, avoiding expression of the transgene in non-target cell types. The Greenberg labs PESCA platform was advanced to commercial readiness through the strategic support of the Q-FASTR program at HMS and the Blavatnik Biomedical Accelerator at Harvard University.

The two technology platforms have unique capabilities to simultaneously engineer AAV capsids to exhibit enhanced cellular tropism, evasion of pre-existing immunity, while maintaining and potentially improving manufacturability. The companys GRE platform focuses on GREs and enhancers that drive cell type-specific expression, disease state-specific expression, and tunable expression levels. These capabilities together are expected to enable Apertura to develop best-in-class gene therapies designed for specific indications.

Our platform has the potential to unlock many new indications for gene therapy, said Kristina Wang, Director of Corporate Development and Board Member of Apertura. We aim to maximize our impact through dedicated internal programs and meaningful partnerships with other biopharma companies and academic groups. Committed to advancing the field of gene therapy, Apertura seeks to collaborate broadly to accelerate impact to patients.

About Apertura Gene TherapyApertura is a biotechnology company opening opportunities for treating currently intractable diseases. We are uniquely positioned to develop genetic medicines by simultaneously engineering AAV capsids, genetic regulatory elements, and payloads to overcome limitations in cellular access, gene expression, pre-existing immunity, and manufacturability. Apertura is committed to growing the field of gene therapy and believes that together we maximize our impact by working with corporate and academic partners, patients, and foundations. Founded on technologies from the Broad Institute and Harvard University, and with support from Deerfield Management Company, the company is based at the Cure, Deerfields innovation campus in New York City. For more information, please visit our website at http://www.aperturagtx.com and follow us on LinkedIn and Twitter.

About Deerfield ManagementDeerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy. The Firm works across the healthcare ecosystem to connect people, capital, ideas and technology in bold, collaborative and inclusive ways. For more information, please visit https://deerfield.com/.

About Harvard Universitys Office of Technology DevelopmentHarvards Office of Technology Development (OTD) promotes the public good by fostering innovation and translating new inventions made at Harvard University into useful products that are available and beneficial to society. Our integrated approach to technology development comprises sponsored research and corporate alliances, intellectual property management, and technology commercialization through venture creation and licensing. More than 90 startups have launched to commercialize Harvard technologies in the past 5 years, collectively raising more than $4.5 billion in financing. To further bridge the academic-industry development gap, Harvard OTD manages the Blavatnik Biomedical Accelerator and the Physical Sciences & Engineering Accelerator. For more information, please visit https://otd.harvard.edu.

See original here:
Apertura Gene Therapy Launches with $67M Series A Financing from Deerfield and an Innovative Technology Platform to Develop Genetic Medicines -...

Global Gene Therapy Medicine Market 2022 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2028 Ripon College Days -…

MarketandResearch.biz has brought the addition of a new report examination on Global Gene Therapy Medicine Market affords detailed coverage of the agency and major market trends with ancient and forecast market data. Furthermore, the report gives thorough research into the local improvements of the market, influencing its improvement all through the forecast period from 2022 to 2028.

The market record contains distinct drivers and restraints, possibilities, and problems that the market will look at throughout the projected horizon. The paper begins with a primary review of the industry, consisting of definitions and applications. The study divides the market length by application, type, and geography, in phrases of extent and value.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketandresearch.biz/sample-request/182774

The research consists of a description of the important thing players in the industry and an itemised analysis in their positions in terms of the global landscape. The future growth prospects of the industry are based on a quick quantitative and qualitative assessment of data acquired from various sources.

The study takes into account a various variety of manufacturers, with business profiles of included

Market breakdown by applications:

Market breakdown by types:

The geographical segments are decided upon by the manufacturing and consumption information.

The major areas included in the report are:

ACCESS FULL REPORT: https://www.marketandresearch.biz/report/182774/global-gene-therapy-medicine-market-growth-status-and-outlook-2021-2026

At first, the document gives an essential define of the commercial agency that covers definitions and applications. The record profiles the crucial members in the business, along with an itemized analysis in their positions towards the global landscape. The file gives the distinctive study for employer profiling of key market players in the global Gene Therapy Medicine market and comparative analysis based on their product offering, business overviews, geographic presence, commercial enterprise strategies, mergers & acquisitions, SWOT analysis, latest developments, and key financial facts.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketandresearch.biz

Read more from the original source:
Global Gene Therapy Medicine Market 2022 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2028 Ripon College Days -...

The Promise of Precision Medicine and Genetic Testing in Alzheimer Disease – AJMC.com Managed Markets Network

Precision medicine and genetic testing will reign supreme when it comes to the future of Alzheimer disease care and treatment advancement, according to Richard S. Isaacson, MD, director of the Alzheimer's Prevention Clinic and associate professor of Neurology at Weill Cornell Medicine and New York-Presbyterian.

Isaacsons session Treatment Updates in Alzheimer's Disease: Tailoring Management and Care Approaches to Improve Outcomes, was presented atthis year'sNational Association of Managed Care Physicians Spring Managed Care Forum, held in Orlando, Florida, April 21-22.

Kicking off his presentation, Isaacson remarked on the recent FDA approval and CMS coverage determination of Aduhelm (aducanumab), the first new treatment for the disease brought to market in nearly 2 decades. The treatment functions by targeting the buildup of amyloid beta plaques in the brain, which are thought to be a pathophysiological driver of the neurodegenerative disease.

Following its controversial launch, CMS announced it would only cover administration if the drug were delivered in a clinical trial setting.

Despite the attention that development garnered from the press and public alike, Isaacson stressed a lesser-known development in Alzheimer disease detectionthat a blood-based biomarker for amyloid exists, offering an alternative to testing of cerebral spinal fluid.

Most people are unaware of [the blood-based biomarker], he said, equating the advancement to a cholesterol test for the brain.

Diagnostic testing is important because even though individuals may exhibit symptoms of the disease at age 85, the disease first starts in the brain at age 55 or 60. It begins in the brain 20 to 30 years before the first symptom of memory loss begins, providing a wide window of potential intervention time, Isaacson explained.

The disease is also a spectrum, based on the presentation of certain clinical symptoms over decades, he stressed. Individuals can have amyloid present in the spinal fluid for years and not exhibit symptoms, with recent data showing the amyloid levels in the blood actually increase prioir to those in spinal fluid.

Alzheimers disease affects 46 million Americans, Isaacson said. Not all of those people are going to get dementia because they're going to die from something else.

With regard to genetic testing, studies have shown presence of the APOE4 gene may increase individuals risk of dementia. However, if individuals have multiple copies of the APOE variantand 10% of the Alzheimer disease population doesthey are at an increased risk of side effects for aducanumab, underscoring the importance of precision medicine.

Genetic testing is controversial, Isaacson said, but the practice opens up a realm of possibilities for precision medicine for those with the highly heterogenous disease.

Lots of different genes can contribute to development of Alzheimer disease, and based on these, patients can and should receive different treatments, he stressed. In a few years, Isaacson expects computer programs to be able to determine polygenetic risk for the disease, taking these genetic factors into account as opposed to singular variants in isolation. But just because an individual is at risk does not mean they will develop the disease.

Another aspect of developing personalized care for this patient population is tracking of bodily metrics like blood sugar, as research has proved poor blood sugar control is associated with cognitive problems.

Currently, no curative medications for Alzheimer disease exist, only disease modifying therapies which provide modest benefits to patients. For these, Isaacson stressed the notion of start low, go slow, to help mitigate or even avoid any potential adverse effects. However, as more and more therapeutic targets are identified in the research, the potential for new treatment grows.

With regard to preventive measures, Isaacson highlighted the protective effects of the Mediterranean diet, regular exercise and sleep schedules, and low levels of stress and blood pressure. Cognitive engagement activities like listening to and practicing music can also help prevent decline.

Although the metabolic benefits of medications like semaglutide have been proven, and this could in turn help reduce Alzheimer disease risk, Isaacson prefers to recommend his patients follow behavioral changes and use devices like continuous glucose monitors to help assess metabolic metrics.

Overall, precision medicine and vascular risk factor care will kind of turn Alzheimer's disease and cognitive decline on its head. I think were just a couple of years away from that, he said.

Based on modifiable risk factors, 4 out of every 10 cases of Alzheimer disease may be preventable, he concluded, but cautioned that even though someone may do everything right, they can still get the disease.

See the rest here:
The Promise of Precision Medicine and Genetic Testing in Alzheimer Disease - AJMC.com Managed Markets Network

Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease (CKD) -…

RenaCARE study expected to be fully enrolled by end of Q2 of 2022

AUSTIN, Texas, April 26, 2022 /PRNewswire/ -- Natera, Inc.(NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the RenaCARE (Renasight Clinical Application, Review and Evaluation) study - a real world, prospective, multi-center clinical study to assess the clinical utility of the Renasight genetic testing panel. The study has already enrolled 1,600 patients across 25 sites, representing leading academic and private nephrology clinics in the U.S., and will enroll up to 2,000 patients. It is expected to complete enrollment in the second quarter of 2022 with a publication expected to be submitted in late 2022.

The study aims to demonstrate how genetic findings impact the management of patient care and examines diagnostic outcomes of patients tested with the Renasight genetic testing panel. In addition, the study will assess patient satisfaction, health knowledge and genetic literacy. This study follows a 2019 publication1 in The New England Journal of Medicine (NEJM) showing that 89% of patients who tested positive with a multi-gene genetic test had actionable clinical implications.

"Chronic kidney disease affects more than 10% of the global population, and our 2019 NEJM study showed roughly a 10% genetic yield among CKD patients," said Ali Gharavi, M.D., chief of the Division of Nephrology at New York-Presbyterian/Columbia University Irving Medical Center, director of the Center for Precision Medicine and Genomics in the Department of Medicine, interim director of the Institute of Genomic Medicine at Columbia University Vagelos College of Physicians and Surgeons, the study's principal investigator and a close collaborator with Kidney Disease: Improving Global Outcomes foundation (KDIGO) and the National Kidney Foundation (NKF). "We're optimistic that this study will show that next-generation sequencing (NGS) multi-gene assays can be used in a real world setting, to inform and guide disease management and help improve patient outcomes."

"We're confident that the RenaCARE study will confirm the high clinical utility shown in prior studies. This will be an important addition to the growing body of evidence showing the value of genetic testing to clarify an undifferentiated diagnosis, identify a genetic subtype within a diagnosis, reclassify a diagnosis, or provide insights for genetic counseling, family planning and clinical trial access," said Hossein Tabriziani, M.D., senior medical director of organ health for Natera.

All patients undergoing testing using the Renasight panel are offered optional pre- and post-test genetic information sessions with a genetic counselor in addition to their test results. Similarly, providers have access to Natera's genetic counselors for questions about the Renasight testing panel and review of test results.

Natera designed and launched the Renasight genetic testing panel with the feedback of general nephrologists, pediatric nephrologists, and transplant nephrologists. Natera has performed over 10,000 Renasight tests to date.

About Renasight

The Renasight test is a germline genetic test that screens for hereditary causes of kidney disease. It is indicated for patients with diagnosed kidney disease and is run from a patient's blood or saliva sample. Providers can use the Renasight test to identify a genetic predisposition, clarify a clinical diagnosis, or identify the etiology of an unknown kidney disease to help inform medical management. Additionally, genetic counseling and familial testing can be offered based on the test result. The test has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.

About Natera

Natera is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit http://www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available atwww.natera.com/investorsandwww.sec.gov.

ContactsInvestor Relations:Mike Brophy, CFO, Natera, Inc., 510-826-2350Media:Kate Stabrawa, Communications, Natera, Inc., 720-318-4080pr@natera.com

References

View original content to download multimedia:https://www.prnewswire.com/news-releases/natera-announces-definitive-study-to-evaluate-the-clinical-utility-of-renasight-in-the-diagnosis-and-management-of-chronic-kidney-disease-ckd-301532625.html

SOURCE Natera, Inc.

Visit link:
Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease (CKD) -...

Pharming receives agreement of Paediatric Investigation Plan and Promising Innovative Medicine designation for leniolisib from UK MHRA – PR Newswire

An agreed Paediatric Investigation Plan (PIP) is the regulatory pathway to market authorization for leniolisib as a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in children

A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme

LEIDEN, the Netherlands, April 26, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or the "Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a positive decision from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) on a Paediatric Investigation Plan (PIP) submission for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3K) inhibitor, for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in patients from 1 year of age to less than 18 years of age. The Company also announces that the MHRA has granted Promising Innovative Medicine (PIM) designation to leniolisib for the treatment of APDS.

A PIP is a development plan aimed at ensuring that the necessary data are obtained to support the marketing authorization of a medicine in the pediatric population. All applications for marketing authorization for new medicines in children require the results of studies as described in an agreed PIP, unless the medicine is exempt due to a deferral or waiver. The leniolisib PIP includes two planned global clinical trials in pediatric patients with APDS, the first in children ages 4-11 years and the second in children ages 1-6 years. The Company expects to initiate recruitment for this pediatric program for leniolisib during the second half of 2022.

A PIM designation indicates that a medicinal product is a promising candidate for the MHRA's Early Access to Medicines Scheme (EAMS), which provides pre-market access to products that are intended for the treatment, diagnosis, or prevention of a life-threatening or seriously debilitating condition and have the potential to address an unmet medical need.

Anurag Relan MD, Pharming's Chief Medical Officer, commented:

"We are pleased to have received agreement of this PIP and the PIM designation from the MHRA, these represent important regulatory milestones as we continue to advance leniolisib for the treatment of APDS, a rare, often debilitating, and sometimes fatal condition. The agreed PIP and the PIM designation further support our confidence in the potential of leniolisib to address APDS, as they provide us with a pathway toward marketing authorization in the United Kingdom. Pharming looks forward to continuing to work with regulatory authorities globally to bring leniolisib to patients with this significant unmet medical need as expeditiously as possible."

Leniolisib, which has received Orphan Drug Designation in Europe, received the same designation from the US Food and Drug Administration on January 30, 2018.

As previously announced, Pharming plans to begin submitting global registration filings for leniolisib in the second quarter of 2022 and, subject to approval, launching the treatment in the US in the first quarter of 2023 and starting a series of European launches in the second half of 2023.

About Activated Phosphoinositide 3-Kinase Syndrome (APDS)

APDS is a rare primary immunodeficiency that affects approximately one to two people per million. Also known as PASLI, it is caused by variants in either of two genes, PIK3CD or PIK3R1, that regulate maturation of white blood cells. Variants of these genes lead to hyperactivity of the PI3K (phosphoinositide 3-kinase delta) pathway.1,2 Balanced signaling in the PI3K pathway is essential for physiological immune function. When this pathway is hyperactive, immune cells fail to mature and function properly, leading to immunodeficiency and dysregulation.1,3 APDS is characterized by severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy.4,5 Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.6 As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma.4-7 The only way to definitively diagnose this condition is through genetic testing.

About leniolisib

Leniolisib is a small-molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K with immunomodulating and potentially anti-neoplastic activities. Leniolisib inhibits the production of phosphatidylinositol-3-4-5-trisphosphate (PIP3). PIP3 serves as an important cellular messenger specifically activating AKT and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Unlike PI3K and PI3K, which are ubiquitously expressed, PI3K and PI3K are expressed primarily in cells of hematopoietic origin. The central role of PI3K in regulating numerous cellular functions of the adaptive immune system (B-cells and, to a lesser extent, T cells) as well as the innate immune system (neutrophils, mast cells, and macrophages) strongly indicates that PI3K is a valid and potentially effective therapeutic target for several immune diseases.

To date, leniolisib has been well tolerated during both a Phase 1 first-in-human trial in healthy subjects and a Phase II/III registration-enabling study.

About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit http://www.pharming.com.

Forward-looking Statements

This press release contains forward-looking statements, including with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, Pharming's ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of its business, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2021 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release.

References:

1. Lucas CL, et al. Nat Immunol. 2014;15:88-97.

2. Elkaim E, et al. J Allergy Clin Immunol. 2016;138(1):210-218.

3. Nunes-Santos C, Uzel G, Rosenzweig SD. J Allergy Clin Immunol. 2019;143(5):1676-1687.

4. Coulter TI, et al. J Allergy Clin Immunol. 2017;139(2):597-606.

5. Maccari ME, et al. Front Immunol. 2018;9:543.

6. Jamee M, et al. Clin Rev Allergy Immunol. 2019;May 21.

7. Condliffe AM, Chandra A. Front Immunol. 2018;9:338

For further public information, contact:Pharming Group, Leiden, The NetherlandsSijmen de Vries, CEO: T: +31 71 524 7400 E: [emailprotected]

FTI Consulting, London, UK Victoria Foster Mitchell/Alex ShawT: +44 203 727 1000

FTI Consulting, USA Jim PolsonT: +1 (312) 553-6730

LifeSpring Life Sciences Communication, Amsterdam, The NetherlandsLeon MelensT: +31 6 53 81 64 27E: [emailprotected]

US PR:Emily VanLareE: [emailprotected]T: +1 (203) 985 5596

EU PR:Dan CaleyE: [emailprotected]T: +44 (0) 787 546 8942

Logo - https://mma.prnewswire.com/media/1454235/Pharming_Group_NV_Logo.jpg

SOURCE Pharming Group N.V.

See the rest here:
Pharming receives agreement of Paediatric Investigation Plan and Promising Innovative Medicine designation for leniolisib from UK MHRA - PR Newswire